BOOKLET OF PARTICIPANTS

UNDER THE AUSPICES OF:

PANCREATIC CANCER SYMPOSIUM

PALAIS DU PHARO
MARSEILLE, FRANCE
WWW.PCS-2015.COM

ORGANISING COMMITTEE:

FRÉDÉRIC ANDRÉ, CRO2, MARSEILLE
LAURENT BARTHOLIN, CRCL, LYON
CORINNE BOUSQUET, CRCT, TOULOUSE
JÉRÔME CROS, HÔPITAL BEAUJON, CLICHY
ÉRIC MAS, CRO2, MARSEILLE
RICHARD TOMASINI, CRCM, MARSEILLE
STÉPHANIE TRUANT, CHRU, LILLE
SOPHIE VASSEUR, CRCM, MARSEILLE
FACULTY & SPEAKERS

FACULTY

S. Antoun, France  E. Hessmann, Germany  M. Hidalgo, Spain  N. Bardeesy, USA  F. Novelli, Italy  K. Olive, USA  E. Costello, United Kingdom  D. Saur, Germany  O. Farges, France  D. Tuveson, USA  A. Kimmelman, USA  M. Korc, USA  M. Vander Heiden, USA  P. Hammel, France

SPEAKERS

S. Antoun, France  N. Bardeesy, USA  P. Chiao, USA  J. Cros, France  C. Bousquet, France  L. Buscail, France  P. Cappello, Italy  P. Cordelier, France  E. Costello, United Kingdom  N. Chuvin, France  S. Dougan, USA  O. Farges, France  F. Guillaumond, France  J. Guillermet-Guibert, France  P. Hammel, France  E. Hessmann, Germany  M. Hidalgo, Spain  N. Kalaany, USA  A. Kimmelman, USA  M. Korc, USA  S. Kugel, USA  L. T. N. Lenk, Germany  J. Morton, United Kingdom  V. Moutardier, France  C. Neuzillet, France  R. Nicolle, France  F. Novelli, Italy  K. Olive, USA  D. Pietrasz, France  J-L. Raoul, France  D. Saur, Germany  P. Sancho, United Kingdom  C. Steele, United Kingdom  G. Su, USA  R. Tomasini, France  D. Tuveson, USA  M. Vander Heiden, USA  S. Vasseur, France  B. Westphalen, Germany

SCIENTIFIC PROGRAM

WEDNESDAY OCTOBER 28TH, 2015

17.00-18.00  📅 Welcome participant
18.00-18.15  📅 OPENING OF THE SYMPOSIUM  by L. Buscail, President of the AFRCP, FR
19.00-19.15  📅 WELCOME TO MARSEILLE  by V. Boyer, Deputy Mayor of Marseille, FR
19.15-20.00  🥂 Local wine and cheese
THURSDAY OCTOBER 29TH, 2015

SESSION I: IMPACT OF MICROENVIRONMENT ON Pancreatic CANCER
Chairs: D. Tuveson & K. Olive

09.00-09.45  KEYNOTE LECTURE: Modelling and targeting the microenvironment of pancreatic cancer by D. Saur, Technical University of Munich, DE

09.45-10.10  Inflammation driven nuclear complexes in pancreatic carcinogenesis and PDAC progression by E. Hessmann, University Medical Center Göttingen, DE

10.10-10.20  Sleep is the enemy: cellular dormancy and cancer stem cell properties are influenced by hepatic alterations in disseminated pancreatic ductal epithelial cells by L. T. N. Lenk, UK SH Kiel, DE

10.20-10.30  Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumor chemoresistance and metastasis by C. Bousquet, INSERM U1037, Toulouse, FR

10.30-11.00  Break

Chairs: É. Mas & F. Novelli

11.00-11.25  α-enolase (ENO1) as therapeutic and immunological target in pancreatic cancer by F. Novelli, University of Turin, IT

11.25-11.50  IL-17 promotes pancreatic cancer progression and limits the anti-tumor responses by P. Cappello, University of Turin, IT - SELECTED PRESENTATION A21

11.50-12.00  Development of immune based therapies for pancreatic cancer by S. Dougan, Dana-Farber Cancer Institute, Boston, US - SELECTED PRESENTATION A3

12.00-12.30  CXCR2 inhibition profoundly suppresses metastases and improves immunotherapy in pancreatic ductal adenocarcinoma by C. Steele, Beatson Institute for Cancer Research, Glasgow, UK - SELECTED PRESENTATION A2

12.30-12.45  Impact of the intra-tumoral microenvironment and the epithelial cells crosstalk in pancreatic carcinogenesis by R. Tomasini, INSERM U1068, Marseille, FR - SELECTED PRESENTATION A7

12.45-13.00  Posters session A and lunch

SESSION II: METABOLISM
Chairs: M. Vander Heiden & N. Bardeesy


15.15-15.40  Identifying metabolic dependencies in pancreatic cancer by A. Kimmelman, Dana-Farber Cancer Institute, Boston, US

15.40-15.50  Pancreatic cancer stem cells are characterized by a distinct metabolic phenotype with limited plasticity by P. Sancho, Barts Cancer Institute, London, UK - SELECTED PRESENTATION A35

15.50-16.00  Metabolism reprogramming of pancreatic adenocarcinoma: when collagen becomes a supply center for epithelial tumour cells by S. Vasseur, INSERM U1068, Marseille, FR - SELECTED PRESENTATION A34

16.00-16.30  Break

Chairs: A. Kimmelman & S. Vasseur


16.55-17.05  Identifying metabolic dependencies in obesity-associated pancreatic cancer by N. Kalaany, Harvard Medical School / Boston Children’s Hospital, Boston US - SELECTED PRESENTATION A31

17.05-17.15  Pancreatic ductal adenocarcinoma lipid signature: identification and characterization of crucial therapeutic metabolic-targets in tumor progression by F. Guillaumond, INSERM U1068 CRCM, Marseille, FR - SELECTED PRESENTATION A36

17.15-17.25  Lessons learned from first-in-man gene therapy clinical trial for pancreatic cancer: targeting tumor metabolism to tackle chemoresistance by P. Cordelier, INSERM U1037, Toulouse, FR - SELECTED PRESENTATION A33

17.25-17.35  Exploring mTOR-dependent vulnerabilities in pancreatic cancer by J. Morton, CRUK Beatson Institute, Glasgow, UK - SELECTED PRESENTATION A30

17.35-18.00  Panel discussion

19.00  Gala dinner at Restaurant La Nautique
FRIDAY OCTOBER 30TH, 2015

SESSION III: PRECLINICAL AND CLINICAL ADVANCES

Chairs: M. Korc & A. Sadanandam

08.30-09.15 **KEYNOTE LECTURE** by N. Bardeesy,
General Hospital and Harvard Medical School, Boston, US

09.15-09.40 **News in the treatment of advanced pancreatic cancer (PC)**
by P. Hammel, Hôpital Beaujon, Clichy, FR

09.40-09.50 Genomic profiling of patient-derived xenografts with pancreatic adenocarcinoma: evaluation of the pacaomics trial pilot phase
by R. Nicolle, Ligue Nationale contre le Cancer, Paris, FR

09.50-10.00 Decrease in phospho-S6 expression under MEK inhibitor (MEKi) treatment: a potential predictive biomarker of response to MEKi alone or in combination with PI3Ki-mTOR inhibitors in pancreatic adenocarcinoma (PAC) in vitro and ex vivo models
by C. Neuzillet, Henri Mondor University Hospital, Créteil, FR

10.00-10.20 Break

Chairs: E. Costello & P. Hammel

10.20-10.45 Causes and consequences of aberrant TGF-beta signaling in pancreatic cancer
by M. Korc, IU Simon Cancer Center
Indiana University School of Medicine, Indianapolis, US

10.45-11.10 Management of pancreatic cancer in France, based on the analysis of the national administrative database
by O. Farges, National analysis of management, Beaujon Hospital, Clichy, FR

11.10-11.20 Prognostic value of circulating tumoral DNA in patients with advanced pancreatic adenocarcinoma
by D. Pietrasz, Paris Descartes University, Paris, FR - **SELECTED PRESENTATION B65**

11.20-11.30 High c-Met expression defines a subset of pancreatic adenocarcinoma with poor prognosis following surgical resection: comparison of three c-Met scoring methods, exploration of underlying mechanisms of c-Met overexpression, and transcriptomic characterization of high c-Met tumors
by J. Cros, Beaujon Hospital, Clichy, FR - **SELECTED PRESENTATION B85**

11.30-11.45 **SYMPOSIUM**
Medical treatment of metastatic pancreatic adenocarcinoma: evolutions?
by J-L. Raoul, IPC, Marseille, FR

11.45-12.15 Panel discussion

12.15-13.45 Posters session B and lunch

SESSION IV: CANCER CELL SIGNALS AND SIGNALING

Chairs: M. Hidalgo & L. Bartholin

13.45-14.30 **KEYNOTE LECTURE**: Integrating mouse models in PDAC treatment
by M. Hidalgo, National Center for Investigation in Oncology (CNIO), Madrid, ES

14.30-14.55 Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitusv
by E. Costello, National Institute for Health Research, Liverpool, UK

14.55-15.05 Loss of SIRT6 reactivates the RNA-binding protein Lin28b to drive pancreatic cancer
by S. Kugel, Massachusetts General Hospital / Harvard Medical School, Boston, US - **SELECTED PRESENTATION B80**

15.05-15.15 Target undruggable mutant kras in mouse model of pancreatic ductal adenocarcinoma
by P. Chiao, The University of Texas N. D. Anderson Cancer Center, Houston, US - **SELECTED PRESENTATION B88**

15.15-15.35 Break

Chairs: D. Saur & J. Iovanna

15.35-16.00 Paracrine signaling in pancreatic ductal adenocarcinoma
by K. Olive, Columbia University Medical Center, New York, US

16.00-16.10 The unique roles of activin and Notch4 signaling pathways in the development of intraductal papillary mucinous neoplasm
by G. Su, Columbia University, New York, US - **SELECTED PRESENTATION B92**

16.10-16.20 Targeted activation of TGFß signaling in pancreatic epithelial cells accelerates kras-induced tumorigenesis
by N. Chuvin, CRC Lyon, FR - **SELECTED PRESENTATION B89**

16.20-16.30 Dclk1 is a novel kras effector and marks pancreatic stem and cancer initiating cells
by B. Westphalen, Ludwig-Maximilians University Munich, DE - **SELECTED PRESENTATION B74**

16.30-16.40 Isoform-specific PI3K-induced signalling differs along pancreatic cancerogenesis but controls the induction of other signalling pathways
by J. Guillermet-Guibert, INSERM U1037, Toulouse, FR - **SELECTED PRESENTATION B79**

16.40-17.00 Panel discussion

17.00 Awards ceremony

Closing remarks by C. Bousquet, CRTC Toulouse, FR & V. Moutardier, AP-HM Hôpital Nord, Marseille, FR